DRUGBright Minds Biosciences Inc.
What is the market doing?
The market is leaning against it: in a downtrend (−29% vs 200-day) and heavily shorted (+12% of shares).
In a downtrend, below its 50- and 200-day averages. Price is −29% vs its 200-day average.
Heavily shorted, settled Sep 30, 2026, more than a week of normal trading to cover, a crowded exit.
Where this answer is blind. Insider selling is often routine (taxes, diversification); only cluster buying is a strong tell.
How DRUG is trading
Bright Minds Biosciences Inc. is −16% over the past year while the S&P 500 is +16%: 32 points behind the market.
1-year return · S&P 500 +16%
- vs 200-day average
- −29%
vs 200-day average · a clear downtrend
- RSI (14)
- 55
RSI (14) · neutral
- Below its 52-week high
- 45%
Below its 52-week high
Details›
- Last close2026-10-23
- $52.39
- 1 monthS&P 500 −0.94%
- −1.0%
- 1 yearS&P 500 +16%
- −16%
- 5 yearsS&P 500 +86%
- +41%
- vs 50-day average$61.84
- −15%
- 52-week high
- $95.99
- 52-week low
- $48.09
- Annualised volatility
- 73%
- Insider selling, net, 6 monthsForms 3/4/5 to 2026-10-22
- $9.8M
| Year | Return |
|---|---|
| 2026 (year to date) | −33% |
| 2025 | +117% |
| 2024 | +2419% |
| 2023 | −61% |
| 2022 | −77% |
| Month | Years | Positive | Average |
|---|---|---|---|
| Jan | 5 | 1 of 5 | +3.8% |
| Feb | 5 | 2 of 5 | −6.6% |
| Mar | 5 | 0 of 5 | −20% |
| Apr | 6 | 2 of 6 | −4.2% |
| May | 6 | 4 of 6 | +5.1% |
| Jun | 6 | 1 of 6 | −11% |
| Jul | 6 | 6 of 6 | +19% |
| Aug | 6 | 3 of 6 | +10% |
| Sep | 6 | 3 of 6 | +1.4% |
| Oct | 6 | 2 of 6 | +643% |
| Nov | 5 | 2 of 5 | −2.0% |
| Dec | 5 | 2 of 5 | −11% |
End-of-day closes from IEX; the S&P 500 comparison uses SPY over the same window. Prices are a reference point, not a basis for trading decisions.
Where the price stands
Its trend against the 50-day and 200-day averages, and the levels it keeps coming back to.
What it has returned
With dividends, year by year, month by month, and by calendar month on average.